Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      CD4-Positive T-Lymphocytes*/virology ; HIV-1*; Chemokines, CC/*blood ; HIV Infections/*blood ; HIV Infections/*immunology; Adult ; Anti-Retroviral Agents/therapeutic use ; Biomarkers/blood ; CD4 Lymphocyte Count ; Cells, Cultured ; Chemokine CCL17/blood ; Chemokine CCL22/blood ; Cohort Studies ; Drug Therapy, Combination ; HIV Infections/drug therapy ; HIV Infections/virology ; Humans ; Middle Aged ; Viral Load ; Young Adult
    • Abstract:
      The chemokine (C-C motif) chemokine ligand 18 (CCL18) is a structural homolog of CCL3 primarily produced by monocyte-derived cells with an M2 phenotype. Elevated levels of CCL18 have been observed in several diseases associated with malignancies and chronic inflammation. The role of CCL18 in Human Immunodeficiency Virus (HIV-1) infection remains unknown. We analyzed expression levels of T helper cell-mediated (TH2) chemokines CCL18, CCL17, and CCL22 by ELISA in plasma collected from HIV-1-infected and healthy donors. In HIV-1-infected individuals, plasma viral loads were monitored by NucliSense HIV-1 QT assay and T cell counts and expression of the activation marker CD38 were determined by flow cytometry. Our data showed a significant increase in plasma levels of CCL18 in HIV-1-infected individuals compared to uninfected controls (p < 0.001) and a significant correlation between CCL18 levels and viral load in untreated patients. No significant difference of CCL18 levels was detected among the HIV-1-infected patients treated with combined antiretroviral therapy (cART) and HIV-1-untreated patients.CCL18 values are negatively correlated with CD4+CD38+ cell numbers and total CD4+ T cell counts in patients with a suppressed viral load. Notably, plasma levels of the TH2 chemokines CCL17 and CCL22 are also elevated during HIV-1 infection. However, no correlation of CCL17 and CCL22 production with CD4+ T cell counts was detected. Presented data shows that the chemokines, CCL17, CCL18, and CCL22 are increased during HIV-1 infection. However, only increased levels of CCL18, a marker of M2 macrophages, correlate with low CD4+ T cell counts in patients with suppressed viral load, raising the possibility that CCL18 and/or CCL18-producing cells may interfere with their reconstitution in HIV-1-infected patients on cART.
    • References:
      J Exp Med. 1998 Jan 5;187(1):129-34. (PMID: 9419219)
      J Infect Dis. 2005 May 15;191(10):1670-9. (PMID: 15838794)
      J Exp Med. 1998 Mar 16;187(6):875-83. (PMID: 9500790)
      Immunol Cell Biol. 2004 Feb;82(1):38-46. (PMID: 14984593)
      PLoS One. 2012;7(4):e34561. (PMID: 22511950)
      Immunol Today. 1993 Mar;14(3):107-11. (PMID: 8096699)
      Eur J Immunol. 1999 Jan;29(1):38-44. (PMID: 9933084)
      J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):287-94. (PMID: 10836750)
      J Leukoc Biol. 2005 Jul;78(1):14-26. (PMID: 15784687)
      Annu Rev Immunol. 2000;18:217-42. (PMID: 10837058)
      Cell Host Microbe. 2016 Mar 9;19(3):304-10. (PMID: 26962941)
      PLoS One. 2011 Jan 18;6(1):e16021. (PMID: 21267454)
      Am J Hum Genet. 2006 Jul;79(1):120-8. (PMID: 16773571)
      J Immunol. 2003 Apr 1;170(7):3843-9. (PMID: 12646652)
      J Immunol. 1998 Nov 1;161(9):5027-38. (PMID: 9794440)
      Int Immunol. 1999 Jan;11(1):81-8. (PMID: 10050676)
      Clin Diagn Lab Immunol. 1995 Nov;2(6):712-8. (PMID: 8574836)
      J Immunol. 1992 Aug 1;149(3):1004-9. (PMID: 1634758)
      Virology. 2017 Apr;504:79-87. (PMID: 28157548)
      Nat Rev Immunol. 2003 Jan;3(1):23-35. (PMID: 12511873)
      Cancer Cell. 2011 Apr 12;19(4):541-55. (PMID: 21481794)
      Blood. 1990 Sep 15;76(6):1110-6. (PMID: 2205307)
      J Exp Med. 2013 Sep 23;210(10):1889-98. (PMID: 23999500)
      Blood. 2002 Feb 15;99(4):1465-73. (PMID: 11830501)
      J Immunol. 1998 Feb 1;160(3):1411-8. (PMID: 9570561)
      J Virol. 2002 Sep;76(18):9011-23. (PMID: 12186885)
      Blood. 2004 Jan 1;103(1):33-9. (PMID: 12969956)
      J Immunol. 2001 Mar 1;166(5):3284-9. (PMID: 11207283)
      Nature. 1997 Jun 12;387(6634):713-7. (PMID: 9192897)
      J Clin Invest. 2012 Mar;122(3):787-95. (PMID: 22378047)
      Nature. 2003 Jul 10;424(6945):213-9. (PMID: 12853962)
      Am J Pathol. 2003 Nov;163(5):2065-75. (PMID: 14578205)
      J Immunol. 1997 Aug 1;159(3):1140-9. (PMID: 9233607)
      Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L494-501. (PMID: 12716654)
      Retrovirology. 2010 Apr 09;7:33. (PMID: 20380696)
    • Grant Information:
      R01 AI043743 United States AI NIAID NIH HHS; R01 AI147731 United States AI NIAID NIH HHS; R03 AI078822 United States AI NIAID NIH HHS; R15 NS108815 United States NS NINDS NIH HHS
    • Accession Number:
      0 (Anti-Retroviral Agents)
      0 (Biomarkers)
      0 (CCL17 protein, human)
      0 (CCL18 protein, human)
      0 (CCL22 protein, human)
      0 (Chemokine CCL17)
      0 (Chemokine CCL22)
      0 (Chemokines, CC)
    • Publication Date:
      Date Created: 20190414 Date Completed: 20201016 Latest Revision: 20230504
    • Publication Date:
      20230504
    • Accession Number:
      PMC6461658
    • Accession Number:
      10.1038/s41598-019-41588-1
    • Accession Number:
      30979916